Former Teleflex Executive Joins Imperative Care’s Board

Imperative Care Inc. has welcomed Tyler Binney to its Board of Directors. The new board member formerly worked at Teleflex and Relievant Medsystems, helping the latter to eventually be acquired by Boston Scientific Corp.

“At Imperative Care, we are intentional about building a seasoned leadership team that reflects a rich blend of strategic insight, diverse perspectives, and a shared commitment to elevate patient outcomes and expand care,” Imperative Care CEO/Board Chairman Fred Khosravi said. “We’re delighted to welcome Tyler at this significant stage in the company’s growth, as we further expand our impact and advance life-saving innovations for patients afflicted by runaway clot.”

Binney has a proven track record of driving growth through strategic leadership and operational expertise. From April 2021 to November 2023, he was president, CEO, and board member at Relievant Medsystems. During his tenure there, he scaled the company’s commercial operations and successfully led its acquisition by Boston Scientific for more than $850 million. Before Relievant, Binney was president and general manager of Teleflex’s Interventional Urology business unit. He also served as vice president of Sales at NeoTract, where he played a key role in the company’s $1.1 billion acquisition by Teleflex.

Binney currently serves as board chairman at iO Urology and a board member at Intrinsic Therapeutics and ProVerum Medical.

“Imperative Care has taken an expansive patient-centered approach to addressing the scourge of stroke and other devastating vascular diseases,” Binney stated. “I am honored to join the company’s Board of Directors as it focuses on applying operational discipline to expand its commercial presence and bring life-saving technologies to as many patients as possible.”

Imperative Care is a commercial-stage medical technology company researching, developing and manufacturing connected innovations to elevate care for people affected by vascular diseases such as stroke and pulmonary embolism. The Campbell, Calif.-based company is addressing specific gaps in treatment and care.